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OBJECTIVE: To evaluate vaginal cone therapy in two phases, passive and active, in women with stress urinary
incontinence.
METHODS: A prospective study was conducted at the Department of Obstetrics and Gynecology, Sa ˜o Paulo
University, Brazil. Twenty-four women with a clinical and urodynamic diagnosis of stress urinary incontinence were
treated with vaginal cones in a passive phase (without voluntary contractions of the pelvic floor) and an active
phase (with voluntary contractions), each of which lasted three months. Clinical complaints, a functional evaluation
of the pelvic floor, a pad test, and bladder neck mobility were analyzed before and after each phase.
RESULTS: Twenty-one patients completed the treatment. The reduction in absolute risk with the pad test was 0.38
(p,0.034) at the end of the passive phase and 0.67 (p,0.0001) at the end of the active phase. The reduction in
absolute risk with the pelvic floor evaluation was 0.62 (p,0.0001) at the end of the passive phase and 0.77
(p,0.0001) at the end of the active phase. The reduction in absolute risk of bladder neck mobility was 0.38
(p,0.0089) at the end of the passive phase and 0.52 (p,0.0005) at the end of the active phase. Complete reversal of
symptomatology was observed in 12 (57.1%) patients, and satisfaction was expressed by 19 (90.4%).
CONCLUSION: Using vaginal cones in the passive phase, as other researchers did, was effective. Inclusion of the
active phase led to additional improvement in all of the study parameters evaluated in women with stress urinary
incontinence. Randomized studies are needed, however, to confirm these results.
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INTRODUCTION
Stress urinary incontinence (SUI) is defined as the
involuntary leakage of urine during effort.
1 It produces
serious social and psychological problems that have a
significant impact on a woman’s health.
1
Normally, the bladder and urethra are supported by
endopelvic fascia as well as by ligamentous and pelvic floor
muscles.
2 Descent of the bladder and urethra has been
observed in women with SUI, and this hypermobility may
result from denervation of the levator ani muscle.
2 Thus,
pelvic floor musculature, composed of both type I (slow)
and type II (fast) muscle fibers, is important in the urinary
continence mechanism.
3
Several treatment options are available for managing SUI.
Techniques aimed at strengthening the pelvic floor muscles
are often considered the first-choice treatment because of
their noninvasive character, the possibility of combining
them with other treatments, the low risk of side effects and
the moderate-to-low costs.
4 According to a review by
Cochrane, pelvic floor muscle exercises must be included
in the first line of conservative management programs for
women with SUI.
5
The first technique was described in 1948 by Kegel,
6 who
prescribed rapid voluntary contractions of the pelvic floor
muscles. The author observed that 70% of the patients
improved or were cured. However, even when provided
with information on the anatomy and function of these
muscles, 30% of the patients were unable to perform
adequate voluntary contraction, instead eliciting contraction
of the rectus-abdominal, thigh adductor, or gluteus max-
imus muscles—some patients performed the Valsalva
maneuver.
7
The use of vaginal cones to strengthen pelvic floor
muscles was initially proposed by Plevnik in 1985.
8 The
patients were instructed to walk for 15 minutes twice a day
with a cone in the vagina, without making a voluntary
contraction despite the sensation of losing the cone. This
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785sensation, however, produced an involuntary contraction of
the pelvic floor musculature, as shown by electromyogra-
phy of the pelvic floor during the use of a vaginal cone.
9
In a study with rats, analysis of the functional and
histological effects of intravaginal electrical stimulation
10
revealed that 5-second contractions increased type II fibers
but not type I fibers.
In terms of the SUI treatment, some authors were equally
successful with both the vaginal cone therapy recom-
mended by Plevnik, which involves slow fibers, and with
the pelvic floor muscle exercises, which involve fast fibers.
11
Thus, we wanted to evaluate the utilization of vaginal
cones in associated passive and active phases; such use
might produce an additional recruitment of type I and II
fibers in the pelvic floor.
METHODS AND MATERIALS
Twenty-four women with SUI, according to clinical and
urodynamic evaluations, were consecutively selected for
study at the Gynecology Division, Department of Obstetrics
and Gynecology, Sa ˜o Paulo University Medical School. This
study was approved by the Internal Review Board of the
institution and all patients signed an informed consent form
prior to the study. The mean age of the patients was 34 years
(28–40). Nineteen women were multiparous, with at least
two vaginal deliveries each; three reported only one vaginal
delivery; one had undergone two cesarean sections; and one
was nulliparous. The average number of vaginal deliveries
per patient was 2.3. All patients were white, and the body
mass index (BMI) mean was 25.5 kg (mean weight, 66 kg).
The diagnosis of SUI was based on clinical history, a
urogynecological examination, and a urodynamic evalua-
tion. During the urogynecological examination, the patients
were assessed and classified according to the pelvic organ
prolapse quantification (POPQ):
12 17 patients were in stage
II, while 7 were in stage I.
The exclusion criteria comprised surgical treatment for
SUI, clinical treatment for SUI in the 6 months prior to the
study, use of medication affecting the lower urinary tract,
inability to contract the pelvic floor muscles voluntarily,
inability to keep cone number 1 (the lightest) in the vagina,
pregnancy, menopause, diabetes mellitus, chronic pulmon-
ary obstructive disease, genital prolapse stage III or IV,
12
neurological abnormalities of the perineal region, cervical
infection, urinary tract infection, pelvic tumors, overactive
bladder, or intrinsic sphincteric deficiency.
Vaginal cones are stainless steel devices with a plastic
coating and a nylon thread at their apex to facilitate their
removal. A set of 5 cones (figure1) of similar shape and
volume was used, numbered from 1 to 5 and weighing 20.0,
32.5, 45.0, 57.5, and 70.0 grams, respectively (FemtoneH,
Bristol Myers Squibb, Brazil).
Prior to the treatment, the patients were taught how to
contract their pelvic floor muscles correctly. The treat-
ment consisted of two 3-month phases. The first was the
passive phase, and the second, the active phase. In the
passive phase, as recommended by the majority of
authors,
2 while in a standing position, the patient
introduced the heaviest cone she could keep in her
vagina with the apex pointing toward the pelvic floor.
T h es e n s a t i o no fl o s i n gt h ec o n ep r o d u c e di n v o l u n t a r y
contractions of the pelvic floor musculature. The patient
initially introduced cone number 1; if she did not feel the
sensation that it was slipping out, cone number 2 was
then inserted; the replacements continued with consecu-
tively heavier weights until a sensation of loss was
perceived. The patient was then instructed to walk and
not to contract her pelvic floor musculature for one
minute and to report any sensation of losing the device.
We thus identified the initial ‘‘passive cone.’’
The subject was instructed to walk for 15 minutes twice a
day with the passive cone in her vagina without voluntarily
contracting her pelvic floor muscles. When the patient no
longer felt the cone was falling from her vagina, the next
heaviest cone was used. This procedure was continued for
three months.
The active phase was initially performed with the
heaviest cone the patient was able to retain in the vagina
in a standing position for one minute via voluntary
contraction of the pelvic floor muscles. To find the correct
cone, the patient started by introducing the next heaviest
device used at the end of the passive phase. If she was able
to retain it in the vagina easily, she tried to use the next
heaviest cone. Replacements continued until the cone fell
from the vagina, in which case, the subject would begin the
active phase with the previous cone. If the patient ended the
passive phase with cone number 5, she would start the
active phase with the same number device.
After identifying the ‘‘active cone,’’ the patient was
instructed to perform 30 voluntary contractions of 5 seconds
each, alternating with 5 seconds of relaxation, twice a day,
in a standing position. When she was able to retain the cone
easily, the next heaviest device was used. The patients were
evaluated once a week by the author, and he determined
whether they were using the vaginal cones correctly.
Three patients abandoned the study after completing the
passive phase and were excluded from the study. One
moved from the city, and the other two preferred to seek
surgical treatment.
Clinical and ultrasonographic evaluations were per-
formed before and after each of the two phases. The clinical
Figure 1 - Vaginal cones.
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786assessment consisted of an analysis of clinical complaints, a
functional pelvic floor evaluation, and a pad test.
Ultrasound was used to estimate bladder neck mobility
and thus to indirectly evaluate pelvic floor muscle
strengthening.
2
The severity of incontinence was subjectively determined
through the patient’s report of her clinical response to the
treatment and her satisfaction with it.
For analytical purposes, the patients were divided in four
groups as follows: a) unchanged; b) improved but unsa-
tisfied with the treatment; c) improved and satisfied with
the treatment; d) completely dry. Satisfaction with the
treatment meant the patient did not want another treatment
option; therefore, she was analyzed only at the end of the
study.
13
Pelvic floor muscle function was evaluated according to
the grading system proposed by Ortiz et al., 1994. The
patients were put into the gynecological position and
instructed to contract the pelvic floor muscles for five
seconds. The following scores were used to report the
results of this procedure:
14
N 0: Neither visual sign nor digital perception of vaginal
muscle contraction
N 1: No visual sign of muscle contraction, but perception of
a weak contraction upon vaginal palpation
N 2: Weak muscle contraction upon both visual survey and
vaginal palpation
N 3: Good muscle contraction at both visual survey and
vaginal palpation but with no resistance to palpation
N 4: Strong muscle contraction at both visual survey and
vaginal palpation but with less than 5 seconds of
resistance to palpation
N 5: Strong muscle contraction at both visual survey and
vaginal palpation with 5 seconds of resistance to
palpation
Musculature was considered weak if the score of the
functional pelvic floor evaluation was less than 3.
15 Urine
loss was evaluated using the 1-hour pad test with a
standardized bladder volume
13,16 when 250 ml were
introduced by catheter into the bladder. Pad weights were
measured in grams, and a weight of less than 2 g was
considered normal.
13,16,17
Bladder neck mobility was assessed by introital ultra-
sound with the patient in a standing position and with an
intravesical volume of 200 to 250 ml, as defined by
transabdominal ultrasonography (Sonochrome, General
Electric) using a 5 MHZ vaginal transducer. The distance
between the bladder neck and the pubic symphysis was
measured at rest and during stress maneuvers (Valsalva).
Measurements were made according to an orthogonal
system of Cartesian coordinates, using the inferior limit of
the pubis symphysis as the point of origin. Bladder neck
mobility from rest to stress was measured in millimeters.
Less than 10 mm of bladder neck mobility was considered
normal.
18
In the statistical analysis, Pearson’s chi-square test,
Fisher’s exact test and Student’s t-test were used to analyze
the pad test, the bladder neck mobility, and the functional
pelvic floor evaluation at the end of each of the two phases.
P,0.05% was considered statistically significant. An inten-
tion-to-treat analysis was also performed.
RESULTS
The results showed that 21 (87.5%) patients completed the
treatment. Three women (13.5%) withdrew from the study:
one moved from the city and the other two requested
surgical treatment (figure 2).
The absolute risk of the pad test (.2 g) at baseline was 1.
At the end of the passive phase, the reduction in absolute
risk was 0.38 (p=0.0034); at the end of the active phase, this
value was 0.67 (p,0.0001) (table 1). In the intention-to-treat
analysis (24 patients), the absolute risk at baseline was 1
(.2 g), while the reduction in absolute risk at the end of the
passive phase was 0.33 (p=0.0039); at the end of the active
phase, this value was 0.58 (p,0.0001) (table 2). When
comparing the variation in mean values between the passive
phase endpoint and the baseline (16.11 g) with that between
the active phase endpoint and the baseline (18.39 g), the
difference was 2.28 g (p=0.61) (table 3).
The absolute risk of the functional evaluation of the pelvic
floor (#3) at baseline was 0.81. At the end of the passive
phase, the reduction in absolute risk was 0.62 (p,0.0001); at
the end of the active phase, this value was 0.77 (p,0.0001)
(table 1). In the intention-to-treat analysis (24 patients), the
absolute risk at baseline was 0.83 (#3), while the reduction
in absolute risk at the end of the passive phase was 0.65
(p=0.0004); at the end of the active phase, this value was
0.66 (p,0.0001) (table 2). When comparing the variation in
mean values between the passive-phase endpoint and the
baseline (1.09) with that between the active-phase endpoint
and the baseline (1.61), the difference was 0.52 (p=0.01)
(table 3).
The absolute risk of bladder neck mobility (.10 mm) at
the baseline was 0.95. At the end of the passive phase, the
reduction in absolute risk was 0.38 (p=0.0089) (table 1); at
the end of the active phase, this value was 0.52 (p=0.0005).
In the intention-to-treat analysis (24 patients), the absolute
risk at baseline was 0.95 (.10 mm), while the reduction in
absolute risk at the end of the passive phase was 0.33
(p=0.01) and 0.45 (p=0.0007) at the end of the active phase
(table 2). Comparing the variation in mean values between
the passive-phase endpoint and the baseline (4.80 mm) with
that between the active-phase endpoint and the baseline
(6.55 mm), the difference was 1.75 mm (p=0.12) (table 3).
With respect to the clinical questionnaire, 12 (57.1%)
patients reported complete recovery; 7 (33.3%) reported
improvement and satisfaction; and 1 (4.8%) reported no
change. Thus, 19 (90.4%) patients were satisfied with the
treatment, and 10 (47.6%) patients, who showed improve-
ment at the end of the passive phase, were found to be cured
at the end of the active phase (table 4). These results were
statistically significant (p=0.0002).
DISCUSSION
There are many available treatment options for SUI. The
techniques aiming at strengthening pelvic floor muscles
lead to reduction in muscle dysfunction, one of the main
causes of SUI.
2
Nevertheless, 30% of the patients are unable to perform
an adequate voluntary contraction.
7 The use of vaginal
cones elicits a specific, effective muscle contraction because
the patient needs to contract the pelvic floor muscles
2,8,15
while concomitantly decreasing accessory muscle contrac-
tions in order to retain the cone in the vagina.
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787Table 1 - Analysis of the pad test, the bladder neck mobility, and the functional pelvic floor evaluation at baseline and
at the end of the passive and active phases.
N
Outcome
before
treatment
(N)
AR of
outcome
before
treatment
Outcome
after
passive
phase (N)
AR of
outcome
after passive
phase
RAR of
outcome
after passive
phase
NNT of
passive
treatment
Outcome
after
active
phase (N)
AR of
outcome
after active
phase
RAR of
outcome
after active
phase
NNT of
active
treat-
ment
Pad test (outcome$2 g) 21 21 1.0 13 0.62
0.38 3 7 0.33 0.67 1
IC 95%
0.17 – 0.58
IC 95%
2-6
IC 95%
0.46 – 0.86
IC 95%
1-2
P=0.0034 P,0.0001
Bladder
neck
mobility (outcome$10mm) 21 20 0.95 12 0.57
0.38 3 9 0.42 0,52 2
IC 95%
0.15 – 0.61
IC 95%
2-7
IC 95%
0.29 - 075
IC 95%
1-3
P=0.0089 P=0.0005
Functional
pelvic
floor
evaluation
(outcome#3) 21 17 0.81 4 0.19
0.62 2 1 0.04 0,77 2
IC 95%
0.38 – 0.85
IC 95%
1-3
IC 95%
0.57 – 0.95
IC 95%
1-2
P,0.0001 P, 0.0001
N- number of patients; RAR: reduction in absolute risk.
AR: absolute riskNNT: necessary number to treat.
Figure 2 - Overview of patients during the treatment.
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788The majority of authors recommend only passive use of
this technique.
8,15,19,20 In our study, cones were used in two
different phases, passive and active, to stimulate the use of
muscle fiber types I (slow) and II (fast). In the passive phase,
type I fibers were stimulated when the contractions were
prolonged.
21 However, in the active phase and during the
exercises proposed by Kegel,
4 there was an increase in the
use of type II fibers.
11,22
The duration of this therapy is controversial. It can last
from oneweek tosixmonths.
2,13,23 Toassessthereal potential
ofa treatment that isaimedatimprovingmusclestrength, the
American College of Sports Medicine
24 recommends that
therapy be continued for at least five months. In our study,
we opted to extend treatment to six months.
There is no consensus as to the methods that may be used
for subjective and objective evaluation of urine loss during
Table 2 - An intention-to-treat analysis of the pad test, the bladder neck mobility and the functional pelvic floor
evaluation at baseline and at the end of the passive and active phases.
N
Outcome
before
treatment
(N)
AR of
outcome
before
treatment
Outcome
after
passive
phase (N)
AR of
outcome
after
passive
phase
RAR of
outcome
after
passive
phase
NNT of
passive
treatment
Outcome
after active
phase (N)
AR of
outcome
after
active
phase
RAR of
outcome
after active
phase
NNT of
active
treatment
Pad test (outcome$2 g) 24 24 1.0 16 0.66 0.33 3 10 0.41 0.58 2
IC 95%
0.14 – 0.52
IC 95%
1-3
IC 95%
0.38 –0.78
IC 95%
1-3
P=0.0039 P,0.0001
Bladder neck mobility
(outcome$10 mm)
24 23 0.95 15 0.62 0.33 3 12 0.50 0.45 2
IC 95%
0.12 – 0.54
IC 95%
2-8
IC 95%
0.24 – 0.67
IC 95%
1-4
P=0.01 P=0.0007
Functional pelvic floor
evaluation
(outcome#3)
24 20 0.83 7 0.29 0.65 2 4 0.16 0.66 2
IC 95%
0.37 – 0.93
IC 95%
1-3
IC 95%
0.45 – 0.87
IC 95%
1-2
P=0.0004 P,0.0001
N- number of patients; RAR: reduction in absolute risk.
AR: absolute risk; NNT: necessary number to treat.
Table 3 - Comparison of the variation in the mean value of the passive-phase endpoint and baseline with that of the
variation in the mean value of the active-phase endpoint and baseline: pad test, bladder neck mobility, and functional
pelvic floor evaluation.
PAD TEST
VARIATION MEAN VALUE OF PASSIVE PHASE MEAN VALUE OF ACTIVE PHASE
AVERAGE 16.11 18.39
STANDARD DEVIATION 11.89 16.84
N 21 21
Average reduction: 2.2800
IC 95%: -11.3717 to 6.8117
P=0.61
BLADDER NECK MOBILITY (Ultrasound)
VARIATION MEAN VALUE OF PASSIVE PHASE MEAN VALUE OF ACTIVE PHASE
AVERAGE 4.80 6.55
STANDARD DEVIATION 3.49 3.72
N 21 21
Average reduction: 1.75
IC 95%: -3.9996 to 0.4996
P=0.1238
FUNCTIONAL PELVIC FLOOR EVALUATION
VARIATION MEAN VALUE OF PASSIVE PHASE MEAN VALUE OF ACTIVE PHASE
AVERAGE 1.0900 1.6100
STANDARD DEVIATION 0.7000 0.6600
N 21 21
Average increase: 0.5200
IC 95%: -0.9443 to -0.0957
P=0.01
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789SUI therapy.
2 In most reported studies, the subjective
evaluation is based on a quality-of-life questionnaire
2,12
with items about the severity of urine loss and with items
requesting assessment of the patient’s condition as satisfied
or unsatisfied.
13 In our sample, two patients were not
satisfied and one was unchanged at the end of the
treatment. This patient scored 0 in her pelvic floor
evaluation and underwent surgery and a biopsy of the
pelvic floor muscle, the result of which demonstrated that
the type II fibers were completely degenerated. She was the
only patient in whom pelvic floor function did not improve.
The results showed that 19 (90.4%) patients were satisfied
with the treatment, and 10 (47.6%) patients, who showed
improvement at the end of the passive phase, were found to
be cured at the end of the active phase. These good results
were probably obtained because of the addition of the active
phase to this therapy, or rather, because of the complemen-
tary recruitment of type I and type II muscle fibers. Had the
passive phase alone been used, as is done in a majority of
the other studies, the results might not have shown such
improvements.
Peattie et al.
20 reported a study in which 30 patients used
vaginal cones in a passive phase for one month and
afterwards performed the exercises recommended by
Kegel
6 for an additional month. Following the vaginal cone
phase, 70% of the patients were found to be completely dry
or to have improved with respect to urinary loss. No clinical
improvement was reported in the second phase, probably
because the patients did not practice the contractions
correctly.
In our study, patients also reported a reduction in urinary
loss in the active phase, increasing the percentage of
completely dry patients from 8.3% at the end of the passive
phase to 57.1% at the end of the treatment. Such a reduction
probably occurred because the use of the cones stimulated
adequate contraction of pelvic floor muscles and taught
them to perform Kegel’s exercises correctly. The patients
were requested to incorporate these exercises into their
daily routine in order to maintain the beneficial effect after
the end of the study.
25
With reference to the objective evaluation of this therapy,
most investigators recommend the pad test, as suggested by
the International Continence Society (ICS).
2,19,20 However,
one may claim that improvement was possibly due to the
variation in intravesical volume.
26 We chose to use the pad
test indicated by the ICS, but we adopted an intravesical
volume of 250 ml, which was perfectly well tolerated by the
patients. We found a significant reduction in the absolute
risk at the end of the passive and active phases, including in
an intention-to-treat analysis, perhaps owing to the com-
plementary recruitment of type I and II muscle fibers during
muscular contraction of the pelvic floor.
Different methods have been described for evaluating the
anatomic support of the bladder and urethra. In this study,
introital ultrasound was used to analyze bladder neck
mobility.
18 Several authors showed that ultrasonography
was a good tool for evaluating the nonsurgical treatment of
patients with SUI.
2,27 Those researchers reported a reduction
in bladder neck mobility in patients using vaginal cones.
27
In our study, there was a significant decrease in absolute
risk at the end of both the passive and active phases,
including the intention to treat. The only patient whose
symptoms were unchanged had 20.8 mm of bladder neck
mobility at the end of the treatment.
A systematic review of studies on vaginal cone use for
SUI treatment
2 showed that the authors reported a 21%
dropout rate. In our study, however, only three patients
discontinued treatment: one moved from the city and the
other two requested surgical treatment. Weekly evaluation
and analysis to check whether the vaginal cones were being
used correctly may explain the discrepancy between the
results of our study and those of the aforementioned
authors.
Kondo et al.
28 observed that 10% of the patients using
vaginal cones reported side effects such as vaginal pain and
increased vaginal discharge; however, no treatment was
required, and there was no need to discontinue therapy. No
side effects were observed in our study.
In conclusion, using vaginal cones in the passive phase, as
other researchers have done, was effective. Inclusion of the
active phase induced additional improvement in all of the
study parameters for women with stress urinary incon-
tinence. Randomized studies are needed, however, to
confirm these results.
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